Our offer is a vaccine against Bubonic and Pulmonary Plague. It was developed by researcher from the Pasteur Institute of Paris who is a WHO collaborating center on Plague.
Plague is still a public health problem in the world and is considers as a re-emerging disease. Yersinia pestis the causative agent is also consider as a potential biological weapon, but no efficient vaccine is available.
The pneumonic plague is considered at high risks to initiate outbreaks. Antibiotic treatment is not sufficient to control plague, and resistant strains have recently emerged. The residual plague mortality in endemic countries remains around 10 %.
Researchers from the Pasteur Institute are developing a vaccine, based on a live attenuated Y.pseudotuberculosis expressing important antigenic Y.pestis peptides. Recent study using this vaccine shows 100% protection against bubonic and pneumonic plague in mice with a single dose. Preliminary humoral and cellular response has been successfully observed.
Advantages
The "Valorisation Sud" Consortium (CVT) is an inter-institutional organisation certified within the framework of investments for the future. With a ten-year endowment of €9 million, the CVT Valorisation Sud is the French national reference organization for transfers of technology and know-how adapted to tropical and equatorial regions and developing countries.
Create your free account to connect with Zepponi Vanessa and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Zepponi
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
